Tissue Regenix Group (LSE:TRX) ROE % Adjusted to Book Value: -6.27% (As of Jun. 2025)


What is Tissue Regenix Group ROE % Adjusted to Book Value?

Tissue Regenix Group LSE:TRX ROE % Adjusted to Book Value is -6.27% as of Jun. 2025. The stock has 5 warning signs investors should review.

Tissue Regenix Group's ROE % for the quarter that ended in Jun. 2025 was -6.08%. Tissue Regenix Group's PB Ratio for the quarter that ended in Jun. 2025 was 0.97. Tissue Regenix Group's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 was -6.27%.

Tissue Regenix Group ROE % Adjusted to Book Value Related Terms

Tissue Regenix Group ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group ROE % Adjusted to Book Value Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.10 -9.00 -5.55 -3.55 -1.31

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.82 -3.50 -0.94 -1.60 -6.27

LSE:TRX vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Tissue Regenix Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's ROE % Adjusted to Book Value falls into.


Tissue Regenix Group ROE % Adjusted to Book Value Calculation

Tissue Regenix Group's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-2.38% / 1.81
=-1.31%

Tissue Regenix Group's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-6.08% / 0.97
=-6.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -6.27% mean?
Tissue Regenix Group (LSE:TRX) has a ROE % Adjusted to Book Value of -6.27% as of Jun. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's ROE % Adjusted to Book Value too high?
Tissue Regenix Group's current ROE % Adjusted to Book Value is -6.27%.
How does Tissue Regenix Group's ROE % Adjusted to Book Value compare to VRTX and REGN?
Tissue Regenix Group's ROE % Adjusted to Book Value of -6.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current ROE % Adjusted to Book Value is -6.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current ROE % Adjusted to Book Value of -6.27%. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current ROE % Adjusted to Book Value is -6.27%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current ROE % Adjusted to Book Value is -6.27% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.